Nathalie Fagniez

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Anas Gazzah, Philippe L. Bédard, Cinta Hierro et al. · Annals of Oncology · 2022 · 81 citations

Pharmacy, Oncology, Pharmacology +17

Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates

Marion Bouillon‐Pichault, Claire Brillac, Céline Amara et al. · The Journal of Clinical Pharmacology · 2017 · 15 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Josep Tabernero, Philippe L. Bédard, Yung‐Jue Bang et al. · Cancer Research Communications · 2023 · 15 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Clemence Pouzin, Leonid Gibiansky, Nathalie Fagniez et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2022 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study

Clemence Pouzin, Michel Tod, Mustapha Chadjaa et al. · CPT Pharmacometrics & Systems Pharmacology · 2022 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17